Gryphon Therapeutics Making Proteins without DNA In the early 1990s, the only practical methods of producing synthetic polypeptides had reached about the 50-amino acid mark, the size of the smallest proteins. After a long odyssey, Gryphon Therapeutics is now making synthetic versions of designer protein drugs. Gryphon's version of erythropoeitin, bought for $155 million in 2002, shows how chemists can tweak a protein drug's properties in a way that genetic engineers cannot. http://cl.extm.us/?fe8e11797360007875-fe2c167377670d78761478
who served for five years as SYNTHESIS editor for Asia passed away on July 25th, 2004. He has been a leading scientist in our field Organic Chemistry over decades. We lost with him one of the pioneers of Asymmetric Synthesis. The quality of his research and his dedication and engagement in our science chemistry has always been a leading example for all of us. He will live on in our hearts.